louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04222933: Effect of Motorized Cryotherapy on Early Effusion, Swelling, and Pain After Anterior Cruciate Ligament Reconstruction
Official title: Effect of Motorized Cryotherapy on Early Effusion, Swelling, and Pain After Anterior Cruciate Ligament Reconstruction: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cryotherapy Effect
Lead sponsor: Hanyang University Seoul Hospital
Sponsor class: OTHER
First posted: 2020-01-10
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To test the efficacy of motorized cryotherapy on early effusion, and pain after ACL reconstruction

Detailed description: To test the efficacy of motorized cryotherapy on early effusion, and pain after ACL reconstruction compared to classical ice bagging

Eligibility criteria: Inclusion Criteria:

* Acute ACL ruptured patient

Exclusion Criteria:

* Combined meniscal injury requiring surgery
* Combined ligament injury requiring surgery
* Combined chondral injury requiring surgery
* Previous surgery history on corresponding knee
* Allergic to cold

Primary outcomes:
measure: Pain after surgery
timeFrame: postoperative day 4
Secondary outcomes:
measure: Effusion after surgery
timeFrame: baseline, postoperative day 4, 7, 14, 6 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Orthopaedic Surgery, Hanyang University, College of Medicine
Study officials:
affiliation: Hanyang University
name: JIN KYU LEE, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03591133: Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)
Official title: Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Participants
Lead sponsor: Taisho Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-07-19
Enrollment: 40
Sex: MALE
Minimum age (years): 20
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: To investigate the safety, pharmacokinetics and pharmacodynamics when administering a single dose of TS-143 to Japanese healthy adult males using a placebo-controlled, double-blind, dose-ascending study, in addition to the effects of meals.


Eligibility criteria: Inclusion Criteria:

1. Subjects with a body-mass index (BMI) of 18.5 to less than 25.0 at the time of the screening tests
2. Subjects judged by the principal investigator or a subinvestigator to be appropriate for participation in the study based on the results of the screening tests and the tests conducted prior to the investigational drug treatment

Exclusion Criteria:

1. Subjects who meet any of the following criteria in the screening tests or the tests conducted on Day -1 and prior to the investigational drug treatment

   * Red blood cell count: ≥ 535 × 10\^4 /μL
   * Hemoglobin: ≥ 16.2 g/dL
   * Hematocrit: ≥ 47.5%
   * Reticulocyte ratio: Outside of the reference value range
2. Subjects who meet any of the following criteria in the screening tests

   * Serum EPO concentration: Outside of the reference value range
   * Ferritin: 30 ng/mL or less, or ≥ 262 ng/mL
3. Subjects who meet any of the following criteria in the vital signs in the screening tests and the tests conducted prior to the investigational drug treatment

   * Blood pressure: Systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg or more
   * Pulse rate: \< 40 bpm, or ≥ 100 bpm
   * Body temperature: ≥ 37.5°C

Primary outcomes:
measure: Incidence of adverse events
timeFrame: 8 days
measure: Plasma concentrations of unchanged form (ng/mL)
timeFrame: 72 hours
measure: Urinary excretions of unchanged form (ng/mL)
timeFrame: 72 hours
measure: Serum erythropoietin (EPO) concentration
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Taisho Pharmaceutical Co., Ltd selected site
Study officials:
affiliation: Taisho Pharmaceutical Co., Ltd.
name: Shigeru Okuyama
role: STUDY_DIRECTOR
References:
citation: Shinfuku A, Shimazaki T, Fujiwara M, Sato F, Watase H, Numazaki T, Kawakita Y, Mutoh M, Yamasaki H, Takayama N, Kato S, Sugimoto T, Maruyama J. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers. Am J Nephrol. 2018;48(3):157-164. doi: 10.1159/000492181. Epub 2018 Sep 3.
Clinical trial NCT00473733: Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Diabetes Mellitus Type 2
Keywords: PATIENTS WITH DIABETES MELLITUS TYPE 2
UNDERGO UPPER ENDOSCOPY
BIOPSIES FOR GLP RECEPTORS EXPRESSION
PCR ANALYSIS
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-05-15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.

We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.

Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.

Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.


Eligibility criteria: Inclusion Criteria:

* 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years

Exclusion Criteria:

* Patients with neurological disease will be excluded

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: Assaf Harofeh Medical Center
Study officials:
affiliation: Ethic committee of Asaaf Harofeh Medical Center
name: Efrat Broide, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06084533: CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
Official title: CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Parkinson Disease
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2023-10-16
Enrollment: 80
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 50 participants with idiopathic PD and up to 30 healthy control participants are to be studied. Some of these participants will be recruited from existing research studies. Others will be recruited from the clinic, the community, and a registry of healthy volunteers.

Brief summary: Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.


Eligibility criteria: Inclusion Criteria:

* Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
* Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion Criteria:

* any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
* history of brain surgery or major head trauma
* major medical/systemic illness
* severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
* major drug abuse
* history of long term use of anti-dopaminergic medication
* chronic treatment with immunomodulatory or anti-inflammatory medications
* weight over 300 lbs
* contraindication to or inability to tolerate MRI

Primary outcomes:
measure: PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease.
timeFrame: At the time of PET scan
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Robert L White, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00004333: Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Tyrosinemia, Type I
Keywords: inborn errors of metabolism
rare disease
tyrosinemia I
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: University of Michigan
First posted: 1999-10-19
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg per day prevents liver failure in at least 1 patient with tyrosinemia type I.

Detailed description: PROTOCOL OUTLINE: Only 2 patients with tyrosinemia type I are known to this research team; others will be treated if found and if clinical conditions permit.

The enzyme inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is administered orally, in 2 divided doses daily with meals.

Patients will be followed closely for side effects attributable to NTBC.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

Tyrosinemia type I No cirrhosis No hepatocellular carcinoma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Michigan
name: Jess G. Thoene
role: STUDY_CHAIR
References:
Clinical trial NCT00377533: Wheelchair Handling Skills of Caregivers: Comparison Between Anti-tip Devices and a New Design
Official title: Wheelchair Handling Skills of Caregivers: Comparison Between Conventional Rear Anti-tip Devices and a New Design
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: wheelchairs
caregivers
skills
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2006-09-18
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Currently available wheelchairs are often fitted with conventional rear anti-tip devices (C-RADs) to prevent wheelchair rear tips. The limitations of C-RADs have provided an incentive for the design of rear anti-tip devices that permit more rear tip without compromising safety (Arc-RADs).

The purpose of this study is to test the hypothesis that caregivers handling occupied wheelchairs equipped with Arc-RADs have higher success rates on RAD-relevant skills than caregivers handling wheelchairs equipped with C-RADs.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* alert, able and willing to follow instructions
* wheelchair users: patients at the Nova Scotia Rehabilitation Centre
* wheelchair users:permission of physician to participate in the study
* caregiver:must provide at least part-time wheelchair-handling care for the wheelchair user in this study, a minimum of one hour per week on average

Exclusion Criteria:

* wheelchair users:suffer from any unstable medical, emotional, or physiological conditions that may interfere with participation
* caregivers:medical condition of their upper limbs, heart or lungs that might cause them discomfort or endanger them when pushing or pulling an occupied wheelchair

Primary outcomes:
measure: Wheelchair Skills Test
timeFrame: day
Secondary outcomes:
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: QEII Health Science Centre
state: Nova Scotia
Study officials:
affiliation: Dalhousie University, QEII Health Sciences Centre
name: Lee Kirby, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02677233: Association Between Vitamin D Deficiency and Preeclampsia: A Case Control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pre-Eclampsia
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2016-02-09
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will be carried out on 90 pregnant women recruited at pre labour room at Ain Shams University Maternity Hospital. They will be divided into preeclamptic group and non preeclamptic group, 45 cases in each one

Brief summary: To find out if lower levels of vitamin D is more prevalent in preeclamptic women


Eligibility criteria: Inclusion Criteria:

* Parity: primigravida.
* Age: 18 - 35 years.
* Singleton pregnancy.
* Gestational age: 36-40 weeks.
* No past history of any medical disorder and with no other medical complications during pregnancy

Exclusion Criteria:

* Women with preexisting medical conditions like rheumatoid arthritis, thyroid, hepatic or renal failure, metabolic bone disease, diabetes mellitus, malabsorption and lupus.
* History of intake of medications influencing bone, vitamin D or calcium metabolism e.g. antiepileptic, theophylline, antitubercular drugs in the last 6 months.
* Women with multiple pregnancy.
* Women with congenital fetal malformation.
* Women with known thrombophilia

Primary outcomes:
measure: vitamin D level in preeclamptic and non preeclamptic women
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02540733: MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes
Official title: MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cerebral Stroke
Diabetes Mellitus
Keywords: cerebral infarction
diabetes
rehabilitation
MRI
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2015-09-04
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: with a definition of stroke within 3 to 7 days after onset

Brief summary: Diabetes mellitus (DM) plays an important role in the occurrence of the cerebral infarction (CI). Clinical studies have demonstrated that the CI patients with DM had a poor prognosis compared with those without DM. Previous magnetic resonance imaging (MRI) studies have shown that patients with DM had abnormalities in cerebral vessels, nerves and functions, similar with the findings in mice models. In this study, with multi-modal MRI technologies, investigators tend to observe structural and functional changes of the brain in both DM and non-DM CI patients and assess their neural rehabilitation using clinical scales in the following 6 months. Investigators also expect to find out dynamic changes of brain structure and function, to reveal the weights of factors including brain blood vessels, nerves and function remodeling related with stroke recovery, as well as the potential mechanism in CI patients with DM.


Eligibility criteria: Inclusion Criteria:

1. ﬁrst-ever ischemic stroke;
2. single infarct in the distribution of the middle cerebral artery;
3. no evidence of hemorrhagic infarction;
4. age greater than 18 years;
5. admission between 3 and 7 days after stroke onset;
6. National Institute of Health Stroke Score (NIHSS) score of 4 to 21 on admission and
7. no thrombolytic or recanalization therapies.

Exclusion Criteria:

1. atrial fibrillation;
2. history of neurological or psychiatric disorders;
3. pre-stroke modified Rankin scale (mRS) \> 1;
4. life expectancy \< 1 year.

Primary outcomes:
measure: modified Rankin scale (mRS)
timeFrame: 6 months
measure: National Institute of Health Stroke Score
timeFrame: 6 months
measure: Barthel index
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The 2nd Affiliated Hospital of Zhejiang University, School of Medicine,
state: Zhejiang
Study officials:
References:
Clinical trial NCT03897933: Erector Spinae Plane Block for Postoperative Pain in Percutaneous Nephrolithotomy Patients: a Retrospective Study
Official title: Erector Spinae Plane Block for Postoperative Pain in Percutaneous Nephrolithotomy Patients: a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Percutaneous Nephrolithotomy
Keywords: Erector spinae block
percutaneous
nephrolithotomy
stone
ultrasound
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2019-04-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A number of 60 patients undergoing PCNL between January 2019 and December 2019 were included in our study. Patients included in the study were those who were operated from the stone diseases.

Brief summary: To evaluate the ability of Erector spina Plane block decrease postoperative pain and analgesia requirements in patients undergoing Percutaneous Nephrolithotomy.

Detailed description: Erector spina Plane block was performed with guided ultrasound at T10 Transverse process level would lead to adequate postoperative analgesia ,in Percutaneous Nephrolithotomy surgeries.

Eligibility criteria: Inclusion Criteria:

* ASA I- ASA II Patients

Exclusion Criteria:

* history of allergy to the study medication
* refusal to participate

Primary outcomes:
measure: opioid consumption
timeFrame: 24 hours after surgery
measure: Verbal analog Pain Scores on rest and movement
timeFrame: 24 hours after surgery
Secondary outcomes:
measure: Demographic data
timeFrame: 24 hours after surgery
measure: incidences of adverse effects (like nausea and vomiting)
timeFrame: 24 hours after surgery
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Sibel Seçkin Pehlivan
state: Talas
Study officials:
affiliation: TC Erciyes University
name: Sibel Pehlivan
role: STUDY_DIRECTOR
References:
citation: Liu X, Huang G, Zhong R, Hu S, Deng R. Comparison of Percutaneous Nephrolithotomy Under Regional versus General Anesthesia: A Meta-Analysis of Randomized Controlled Trials. Urol Int. 2018;101(2):132-142. doi: 10.1159/000491021. Epub 2018 Jul 20.
citation: Elkassabany N, Ahmed M, Malkowicz SB, Heitjan DF, Isserman JA, Ochroch EA. Comparison between the analgesic efficacy of transversus abdominis plane (TAP) block and placebo in open retropubic radical prostatectomy: a prospective, randomized, double-blinded study. J Clin Anesth. 2013 Sep;25(6):459-65. doi: 10.1016/j.jclinane.2013.04.009. Epub 2013 Aug 17.
citation: Gurkan Y, Aksu C, Kus A, Yorukoglu UH, Kilic CT. Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: A randomized controlled study. J Clin Anesth. 2018 Nov;50:65-68. doi: 10.1016/j.jclinane.2018.06.033. Epub 2018 Jul 2.
Clinical trial NCT05248633: Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Official title: Bortezomib-lenalidomide-dexamethasone Combined With Radiotherapy for Newly Diagnosed Solitary Plasmacytoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Solitary Plasmacytoma
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2022-02-21
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Solitary plasmacytoma (SP) is characterized by a localized mass of clonal plasma cells with no or minimal bone marrow plasmacytosis. It can present either as EMP or SBP. Radiotherapy is the first-line treatment with high response rate. However, 65-84% SBP patients and 25-35% EMP patients progress at 10 years. We aimed to investigate whether adjuvant bortezomib based chemotherapy with radiotherapy could prolong event-free survival in treatment-naive SP patients compared to that with radiotherapy alone.


Eligibility criteria: Inclusion Criteria:

* treatment-naïve SP.

Exclusion Criteria:

* Not appropriate for radiotherapy.
* ECOG \> 2.
* Co-morbidity of uncontrolled infection.
* Co-morbidity of other active malignancy.
* Patients in pregnancy or lactation.
* Prior or concurrent pulmonary embolism.
* Patients not able to tolerate thrombosis prophylaxis, bortezomib, lenalidomide or dexamethasone.
* Seropositive for human immunodeficiency virus, seropositive for hepatitis C, or HBV-DNA \> 1000 copies/mL.
* Myocardial infarction, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias within 6 months prior to enrollment.
* Grade 2 or higher neuropathy according to National Cancer Institute Common Terminology Criteria for Adverse Events.
* Neutrophil \<1×10E9/L，hemoglobin \< 8g/dL，or platelet \< 75×10E9/L.
* Severely compromised hepatic or renal function: ALT or AST \> 3 × ULN, total bilirubin \> 1.5 × ULN，or eGFR \< 40mL/min.

Primary outcomes:
measure: event-free survival
timeFrame: 2 years
Secondary outcomes:
measure: overall survival
timeFrame: 2 years
measure: response rate
timeFrame: 2 years
measure: adverse events
timeFrame: collected until 30 days after treatment completion
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
References: